{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG002","value":"0"}]}],"title":"Partial response (PR)"},{"categories":[{"measurements":[{"comment":"There were 0 participants who received 50 mg BID of dasatanib who had a minimal response.","groupId":"OG000","value":"NA"},{"groupId":"OG002","value":"12.2"}]}],"title":"Minimal response (MR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Duration of response calculated for those with best response=CR (M-protein \\[MP\\] undetectable by immunofixation \\[IF\\], ≤5% plasma cells in bone marrow, no soft tissue plasmacytomas); VGPR (MP detectable by IF, or ≥90% drop in serum \\[S\\] MP and urine \\[U\\] MP\\<100 mg/24h); PR(≥50% drop in S MP and ≥90% drop in U MP or U protein \\<200 mg/24h, ≥50% drop in BL ST PC size); or MR (≥25% to \\<50% drop in S MP and ≥50% to \\<90% drop in U MP and ≥25% to \\<50% drop in BL ST PC). Duration of response calculated from day criteria for CR, VGPR, PR, and MR were met until progression or death, whichever came first.","groups":[{"description":"Dasatinib, 50 mg administered BID, with 1.0 mg/m\\^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg QD, was administered the day of and 1 day after each bortezomib dosing. In a 21-day cycle, bortezomib was administered by IV bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, BID. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib.","id":"OG000","title":"Dasatinib, 50 mg BID"},{"description":"Dasatinib, 100 mg, given QD with 1.3 mg/m\\^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg QD, was administered the day of and 1 day after each bortezomib dosing. In a 21-day cycle, bortezomib was administered by IV bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, QD in the morning. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib.","id":"OG001","title":"Dasatinib, 100 mg QD"},{"description":"Dasatinib, 140 mg, administered QD with 1.3 mg/m\\^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg QD, was administered the day of and 1 day after each bortezomib dosing.In a 21-day cycle, bortezomib was administered by IV bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, QD in the morning. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib.","id":"OG002","title":"Dasatinib, 140 mg QD"}],"paramType":"NUMBER","populationDescription":"All response-evaluable participants who achieved a response.","reportingStatus":"POSTED","timeFrame":"First occurrence of response to disease progression or death, whichever occurred first (maximum reached: 12.2 months)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}